US Patent 9,050,309: Claim Scope, Expiration, Orange Book Status, and Omega-3 Patent Landscape

US Patent 9,050,309 protects a narrow omega-3 pharmaceutical composition defined by EPA, DHA, DPA, and the predominance of free fatty acids. The core claim requires EPA at 50% to 60%, DHA at 17% to 23%, DPA at 1% to 8%, and at least 90% of total polyunsaturated fatty acids in free-acid form. Dependent claims raise the free-acid threshold to 95%, increase the minimum DPA content, and add unit-dose limitations of at least 500 mg or approximately 1 gram.

The claim structure is consistent with an omega-3 carboxylic-acid product such as the former Epanova development program, rather than with ester-based products such as Lovaza, Omtryg, or Vascepa. The patent does not claim EPA alone, a therapeutic indication, a manufacturing process, or a specific capsule shell.

What does US Patent 9,050,309 cover?

US 9,050,309 covers a pharmaceutical composition containing a defined mixture of long-chain polyunsaturated fatty acids:

Component	Required concentration in independent claim 1
EPA	50% to 60% by weight
DHA	17% to 23% by weight
DPA	1% to 8% by weight
Polyunsaturated fatty acids in free-acid form	At least 90% by weight

The claim requires all limitations simultaneously. A composition with the correct EPA level but insufficient DHA, excessive DPA, or predominantly esterified fatty acids would not satisfy claim 1.

The patent is composition-focused. It does not require:

A particular disease or treatment method
A specified excipient
A particular dosage regimen
A particular capsule material
A particular purification process
A specific EPA-to-DHA ratio outside the stated ranges

The patent’s practical value depends on whether a commercial product contains the claimed fatty-acid profile in substantially free-acid form.

How do the claims of US 9,050,309 differ?

Claim 1: Core composition claim

Claim 1 is the principal infringement risk. It requires:

EPA between 50% and 60% by weight;
DHA between 17% and 23% by weight;
DPA between 1% and 8% by weight; and
at least 90% of the polyunsaturated fatty acid content in free-acid form.

A product falls within the literal scope only if each limitation is met. The concentration ranges are closed numerical ranges in ordinary claim construction. A product containing 60.1% EPA or 22.9% DHA may fall outside the literal range, subject to measurement methodology, claim construction, and any doctrine-of-equivalents analysis.

Claim 2: Higher free-acid threshold

Claim 2 narrows claim 1 by requiring at least 95% of the polyunsaturated fatty acids to be in free-acid form. It is relevant to highly purified omega-3 carboxylic-acid products with minimal esterified or otherwise chemically modified fatty acids.

A product satisfying claim 2 necessarily satisfies the free-acid limitation of claim 1, assuming the remaining compositional limitations are met.

Claims 3 through 9: DPA concentration ladder

Claims 3 through 9 progressively increase the minimum DPA content:

Claim	Minimum DPA concentration	Maximum DPA concentration
3	1.5%	8%
4	2.0%	8%
5	2.5%	8%
6	3.0%	8%
7	3.5%	8%
8	4.0%	8%
9	4.5%	8%

Each claim remains subject to the EPA, DHA, and free-acid requirements inherited from claim 1.

The dependent claims create a fallback hierarchy. A defendant may avoid claim 9 because its product contains less than 4.5% DPA while still facing potential exposure under claim 3 or claim 1.

Claims 10 and 11: Unit-dose limitations

Claim 10 requires a unit dose containing at least 500 mg of the composition. Claim 11 narrows that limitation to a unit dose of about 1 gram.

These limitations are directed to the amount of the composition per dosage unit, not necessarily the amount of EPA. A 1-gram capsule containing approximately 850 mg of omega-3 fatty acids could satisfy the unit-dose limitation if the claim’s compositional requirements are also met.

The phrase “about 1 gram” introduces ordinary claim-construction issues concerning acceptable manufacturing and labeling variation. It does not automatically require exactly 1,000 mg.

What formulations are protected by US 9,050,309?

The patent protects formulations in which the claimed omega-3 fatty acids are predominantly free acids. This distinction separates the patent from products based primarily on ethyl esters or triglycerides.

Free fatty-acid formulations

A free-fatty-acid formulation contains EPA, DHA, and DPA as carboxylic acids rather than as ethyl esters. A product with 90% or more of its polyunsaturated fatty acids in free-acid form can satisfy claim 1. A formulation with at least 95% free acids may fall within claim 2.

The claim does not expressly require all fatty acids to be free acids. Up to 10% of the polyunsaturated fatty acids may be in another form under claim 1, subject to the specification and claim construction.

Ester-based formulations

Lovaza and Omtryg contain omega-3-acid ethyl esters. Vascepa contains icosapent ethyl, an EPA ethyl ester. Those products generally do not satisfy the free-acid limitation merely because they contain EPA or DHA.

An ester-based product could create risk only if the relevant analytical composition, after accounting for the claimed measurement basis, falls within the free-acid limitation. The chemical identity of the active ingredient is therefore central to infringement analysis.

Excipients and dosage forms

The claims do not limit the composition to softgels, hard capsules, liquid formulations, or a particular excipient system. A product in any dosage form could potentially fall within the claims if it meets the claimed fatty-acid composition.

How strong is the patent estate for US 9,050,309?

The patent has moderate claim breadth but a narrow product perimeter.

Strengths

The composition claim can cover a product without requiring proof of a particular treatment indication. A generic or competitor that reproduces the claimed EPA-DHA-DPA profile in free-acid form could face composition-based infringement exposure even if it uses a different label or dosage schedule.

The dependent claims also provide multiple DPA thresholds. That structure can preserve some protection where a competitor adjusts DPA downward but remains within the broader 1% to 8% range.

Limitations

The independent claim requires a relatively specific composition. Products outside any one of the EPA, DHA, or DPA ranges may avoid literal infringement. The free-acid limitation further narrows the field.

The claims do not independently protect:

EPA-only products;
DHA-dominant products;
ethyl ester products;
triglyceride products;
a method of reducing triglycerides;
a manufacturing process;
a specific purification technique; or
a specific commercial brand.

The patent’s enforceability would also depend on written-description, enablement, anticipation, obviousness, and claim-construction issues. The numerical ranges create potential validity disputes based on prior-art omega-3 compositions and whether the claimed combination was predictable from known fish-oil purification methods.

When does US Patent 9,050,309 lose exclusivity?

The patent issued on June 9, 2015. Its ordinary statutory term is generally calculated from the relevant nonprovisional or international application filing date, not from the issue date.[1]

The public claim text alone does not establish the final expiration date, patent-term adjustment, terminal disclaimer, or any patent-term extension. The expected term appears to fall in the late 2020s based on the patent family’s priority and filing history. Any precise freedom-to-operate conclusion must use the USPTO patent-term data and the complete family record.

Event	Date or status
Patent	US 9,050,309
Issue date	June 9, 2015
Subject matter	EPA/DHA/DPA free-fatty-acid composition
Expected statutory term	Late 2020s, subject to USPTO term calculation
Patent-term adjustment	Must be confirmed from USPTO records
Patent-term extension	No extension is established by the supplied claim text
Orange Book listing	No confirmed listing associated with an approved US product

The patent should not be treated as expired solely because the related drug program was discontinued. Patent expiration and product commercialization are separate questions.

What is the FDA and Orange Book status of the related product?

The claim profile is associated with an omega-3 carboxylic-acid formulation developed by Omthera Pharmaceuticals and later pursued by AstraZeneca under the Epanova program. AstraZeneca acquired Omthera in 2013 in a transaction reported at approximately $323 million.[2]

Epanova was developed as a free-fatty-acid omega-3 product for severe hypertriglyceridemia. The US program did not result in a commercially established FDA-approved product comparable to Lovaza or Vascepa. AstraZeneca discontinued further development after the STRENGTH cardiovascular outcomes trial failed to show the expected benefit and was stopped early.[3]

Because an Orange Book listing requires an approved product and an associated approved application, US 9,050,309 should not be assumed to have an active Orange Book listing. The patent therefore does not create the standard listed-patent Paragraph IV pathway associated with an approved reference drug.

Are there Paragraph IV challenges to US 9,050,309?

No established Paragraph IV challenge can be inferred from the claim text, and the patent’s apparent relationship to a discontinued or unapproved product limits the likelihood of a conventional ANDA dispute.

A Paragraph IV certification is generally made against a patent listed for an approved reference drug under the Hatch-Waxman framework. If the associated free-fatty-acid product was not approved and marketed as a reference listed drug, an ANDA applicant would not ordinarily use that product as the basis for a conventional abbreviated application.

Potential challenges could instead arise through:

A declaratory-judgment action;
A future NDA or 505(b)(2) application;
An infringement action against a non-approved commercial product;
A validity challenge based on prior art; or
A freedom-to-operate dispute involving an alternative omega-3 composition.

The absence of a conventional Paragraph IV case does not establish that the patent is immune from invalidity or noninfringement challenges.

What patent litigation affects US 9,050,309?

No major US litigation involving this patent is established by the facts supplied. The principal commercial omega-3 patent disputes have generally involved other products and patent families.

The leading comparison points are:

Product	Principal active form	Relationship to US 9,050,309
Epanova program	Free fatty-acid omega-3 mixture	Closest technical profile
Lovaza	Omega-3-acid ethyl esters	Generally outside free-acid limitation
Omtryg	Omega-3-acid ethyl esters	Generally outside free-acid limitation
Vascepa	Icosapent ethyl	EPA ethyl ester; lacks the claimed DHA/DPA profile
Generic fish oil	Variable triglyceride, ester, or free-acid content	Product-specific analysis required

Amarin’s Vascepa litigation, including cases involving generic icosapent ethyl, concerned Vascepa patents and indication-specific claims rather than the EPA/DHA/DPA free-acid combination in US 9,050,309.[4]

How does US 9,050,309 compare with competing omega-3 patents?

Compared with Lovaza patents

Lovaza-related patents and regulatory exclusivity centered on omega-3-acid ethyl esters and methods of treating hypertriglyceridemia. US 9,050,309 instead requires free-acid predominance and a specific DPA range. A Lovaza-type product is therefore structurally different.

Compared with Vascepa patents

Vascepa contains purified EPA ethyl ester and does not contain the claimed combination of EPA, DHA, and DPA. The patent is not a direct composition barrier to Vascepa or its authorized generics.

Compared with generic fish-oil products

Generic fish-oil products vary substantially in fatty-acid composition and chemical form. A product containing triglyceride-bound EPA and DHA is less likely to satisfy the free-acid limitation. A highly purified free-acid mixture with EPA near 50% to 60%, DHA near 17% to 23%, and DPA within 1% to 8% presents the greatest risk.

What generic entry risks exist?

The most credible design-around strategies are:

Use an ethyl ester or triglyceride form rather than free acids.
Adjust EPA outside the 50% to 60% range.
Adjust DHA outside the 17% to 23% range.
Reduce DPA below 1%.
Increase or reduce DPA beyond the claimed range.
Use an EPA-only composition.
Use a DHA-dominant composition.
Develop a product containing less than 90% free-acid polyunsaturated fatty acids.

A competitor cannot rely solely on a changed brand name, capsule size, or indication. The composition and analytical testing would control the principal infringement analysis.

What manufacturing and IP barriers remain?

The central technical barrier is the production of a stable, scalable, highly purified free-fatty-acid mixture with reproducible EPA, DHA, and DPA percentages. Manufacturing controls would need to address oxidation, odor, impurity removal, fatty-acid distribution, and batch-to-batch consistency.

The patent does not expressly claim the manufacturing method. A competitor may therefore seek a noninfringing process that produces a composition outside the claimed ranges. Separate process, purification, formulation, stability, or delivery patents could still create additional barriers.

Because the claims are concentration-based, analytical methods are commercially important. Disputes may focus on:

Whether percentages are measured by weight of the total composition or total fatty acids;
Whether esterified and free fatty acids are separately quantified;
Whether DPA includes all relevant positional or geometric isomers;
Whether measurement variability moves a batch across a claim boundary; and
Whether the claim requires the stated percentages in the finished product or active fatty-acid fraction.

Key Takeaways

US 9,050,309 is a narrow composition patent for an EPA/DHA/DPA omega-3 mixture.
Claim 1 requires EPA at 50% to 60%, DHA at 17% to 23%, DPA at 1% to 8%, and at least 90% free-acid polyunsaturated fatty acids.
Claims 2 through 9 create narrower free-acid and DPA thresholds.
Claims 10 and 11 cover unit doses of at least 500 mg and approximately 1 gram.
The patent is technically closest to the Epanova free-fatty-acid program.
Lovaza, Omtryg, and Vascepa are materially different because they use ester-based or EPA-only compositions.
No conventional Paragraph IV risk is apparent without an approved reference product and Orange Book listing.
The principal generic design-around routes are esterification, changing the EPA/DHA/DPA profile, or reducing free-acid content below the claimed threshold.
The final expiration date requires the USPTO patent-term record rather than the claim text alone.

FAQs

Does US 9,050,309 cover Vascepa?

No. Vascepa contains icosapent ethyl, an EPA ethyl ester, and does not have the claimed EPA-DHA-DPA free-acid composition.

Does US 9,050,309 cover Lovaza?

Generally no. Lovaza contains omega-3-acid ethyl esters, while the patent requires at least 90% of the polyunsaturated fatty acids to be in free-acid form.

Can a product avoid the patent by containing 0.9% DPA?

A product with less than 1% DPA would fall outside the literal DPA range of claim 1, subject to claim construction and any doctrine-of-equivalents analysis.

Is a 1-gram capsule automatically covered by claim 11?

No. A 1-gram unit dose must also satisfy the EPA, DHA, DPA, and free-acid limitations inherited from claim 1.

Does discontinuation of Epanova invalidate US 9,050,309?

No. Product discontinuation does not itself cancel an issued patent. Patent enforceability depends on expiration, maintenance, validity, terminal disclaimers, and other legal factors.

References

United States Patent and Trademark Office. (n.d.). US Patent No. 9,050,309. USPTO Patent Center.
AstraZeneca. (2013). AstraZeneca to acquire Omthera Pharmaceuticals. AstraZeneca press release.
AstraZeneca. (2020). AstraZeneca announces termination of STRENGTH trial of Epanova. AstraZeneca press release.
U.S. Food and Drug Administration. (2019). Vascepa: Icosapent ethyl prescribing information and regulatory history. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	9,050,309	⤷ Start Trial		Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013201793	⤷ Start Trial
Brazil	112014016788	⤷ Start Trial
Canada	2860512	⤷ Start Trial
Chile	2014001803	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,050,309

Which drugs does patent 9,050,309 protect, and when does it expire?

Summary for Patent: 9,050,309